Babyscreen provides detailed analyses in pregnancy and fetal diagnostics, utilizing the Vanadis NIPT platform developed in Sweden for non-invasive prenatal testing. This service enables expectant parents to obtain accurate genetic information about their fetus, addressing the need for reliable prenatal screening options.
Funding
Funding not disclosed
Founders
Product
Problem
Expectant parents often seek accurate and early information about their fetus's genetic health to alleviate anxiety and prepare for potential health challenges. Traditional prenatal screening methods can be invasive and carry risks, while less accurate non-invasive options may lead to unnecessary worry or further testing.
Solution
Babyscreen offers non-invasive prenatal testing (NIPT) and ultrasound services, providing detailed analyses of pregnancy and fetal diagnostics. Utilizing the Vanadis NIPT platform, a Swedish-developed technology, Babyscreen analyzes cell-free fetal DNA from a maternal blood sample to screen for common chromosomal abnormalities, including Trisomy 13, 18, and 21, with high precision. The platform's automated process minimizes inconclusive results, reducing parental anxiety. Babyscreen also offers a range of ultrasound services, including viability, early, routine, and growth scans, performed by experienced and certified medical professionals using state-of-the-art 3D/4D ultrasound technology.
Target Audience
The primary target audience includes expectant parents seeking early and accurate information about their fetus's health, as well as IVF patients requiring monitoring during fertility treatments.
Features
- Non-invasive prenatal testing (NIPT) using the Vanadis platform for high-accuracy screening of Trisomy 13, 18, and 21
- Option to determine fetal sex with 99.8% accuracy
- Reduced risk of inconclusive results compared to traditional NIPT platforms (less than 0.09%)
- Viability ultrasound to confirm fetal heartbeat, number of fetuses, and gestational age from week 6+0
- Early ultrasound for detailed assessment of fetal organs, skull, umbilical cord, and placenta from week 12+4
- Routine ultrasound (week 18+0 to 20+0) for standardized anatomical review and dating
- Growth control ultrasound to monitor fetal growth and development, especially in high-risk pregnancies
- 3D/4D ultrasound technology for high-quality imaging
- Secure digital delivery of ultrasound images and videos via Tricefy
- Option for NIPT home sampling kit